ClinicalTrials.gg
TerminatedNCT01955629AMORUpdated Apr 18, 2016Results posted

Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

A Phase 1/2 interventional study of Aflibercept AVE0005 and Oxaliplatin in Colorectal Cancer Metastatic, sponsored by Sanofi. Terminated at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-18.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The study enrollment was prematurely halted due to safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing aflibercept in Colorectal Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. aflibercept · Colorectal Neoplasms.

Enrollment
21st of 24
4 · median 63
Started
2013
with 1 other
Phase 1/2
2 of 24
none open now
Registered
13th of 24
by date
Lead sponsor
8 of 24
Sanofi

Among the 24 studies testing aflibercept in Colorectal Neoplasms, this one is the 21st largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 1/2, and was the 13th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

1 of the 24 studies testing aflibercept in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing aflibercept in Colorectal Neoplasms, or all of them as a file.
02

Study summary

Primary Objectives:

Study Part 1: To determine the recommended dose for the aflibercept, oxaliplatin and capecitabine (XELOX) combination to be used in the Part 2 of the study.

Study Part 2: To assess the percentage of participants without progression of the disease at 6 months after the start of maintenance therapy with aflibercept single-agent, following the first-line induction therapy with XELOX and aflibercept combination in participants with previously untreated metastatic colorectal cancer.

Secondary Objective:

Study Part 2: Include the evaluation of progression free survival, overall survival, response to treatment, the overall safety (during induction and maintenance therapy) and the assessment of aflibercept pharmacodynamics and biomarkers parameters.

Read the detailed description

The duration of the study for each participant includes a period for screening of up to 3 weeks, study drug administrations every 3 weeks up to disease progression, unacceptable toxicity or participant's refusal of further study treatment, followed by a minimum of 30-day follow-up after the last study treatment administration.

After study treatment discontinuation each participant will be followed-up until death, participant's refusal or end of study (whichever comes first).

This trial is being conducted in Europe, where the INN designation for the study molecule is "aflibercept" and this term is therefore used throughout the synopsis. In the US, the US proper name is "ziv-aflibercept".

03

Conditions studied

  • Colorectal Cancer Metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically-proven adenocarcinoma of the colon or rectum.
  • disease not amenable to potentially curative treatment (i.e. unresectable).
  • as assessed by (RECIST) criteria.
  • No prior systemic anti-cancer treatment for metastatic disease.
  • No prior treatment after resection of distant metastases.
  • No prior treatment with angiogenesis inhibitors.

Exclusion criteria

Exclusion criteria:

  • Age \<18 years.
  • Performance status >/= 2.
  • Less than 4 weeks from prior radiotherapy or prior surgery (or until the surgical wound is fully healed).
  • Treatment with any other product within the prior 28 days.
  • Other prior neoplasm.
  • History of , active seizure disorder, uncontrolled spinal cord compression, or carcinomatous meningitis, or new evidence of brain or .
  • Any of the following within the prior 6 months: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, severe congestive heart failure, stroke or .
  • Any of the following within the prior 3 months: moderate/severe gastrointestinal bleeding/hemorrhage, treatment resistant peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism or other uncontrolled thromboembolic event.
  • Deep vein thrombosis within the prior 4 weeks.
  • Any severe acute or chronic medical condition, which could impair the ability of the participant to participate in the study.
  • Inadequate bone marrow, liver and renal function: neutrophils \< 1.5x10\^9/L, \< 100x10\^9/L, \< 9.0 g/dL, total >1.5 x upper normal limit (), transaminases >3 x ULN (unless liver are present), alkaline phosphatase >3 x ULN (unless liver metastasis are present), serum creatinine > 1.5 x ULN.
  • Participants on anticoagulant therapy with warfarin.
  • Symptomatic peripheral sensory neuropathy.
  • Inability to take oral medications.
  • Prior history of chronic enteropathy, inflammatory enteropathy, chronic diarrhea, malabsorption syndrome, unresolved bowel obstruction/sub-obstruction, surgery more extensive than hemicolectomy, extensive small intestine resection with chronic diarrhea.
  • Known dihydropyrimidine dehydrogenase deficiency.
  • known history of to aflibercept.
  • Any to administer oxaliplatin or capecitabine as per package insert of each drug.
  • Urine protein-creatinine ratio (UPCR) >1 on morning spot urinalysis or proteinuria > 500 mg/24-h.
  • Uncontrolled hypertension within the prior 3 months.
  • Evidence of bleeding predisposition or underlying coagulopathy, non-healing wound.
  • Pregnant or breast-feeding women.
  • Participants with who do not agree to use an accepted effective method of .

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Aflibercept + XELOX (Oxaliplatin and Capecitabine)

    Aflibercept 6 mg/kg every 3 weeks (q3w) in combination with Oxaliplatin 100 mg/m\^2 q3w and Capecitabine 850 mg/m\^2 twice daily orally (from Day 1 to Day 14 of each cycle), up to 6 cycles as induction therapy, followed by aflibercept 6 mg/kg q3w as maintenance therapy up to disease progression or unacceptable toxicity or participant's refusal of further treatment.

    Drug: Aflibercept AVE0005 · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous

    Also known as: Zaltrap

  • Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous

    Also known as: Eloxatin, SR96669

  • Pharmaceutical form: Tablets; Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)

    DLTs were assessed using the national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) version 4.03. DLTs were defined as any of following AEs: grade 4 neutropenia lasting \>7 consecutive days; febrile neutropenia or neutropenic infection; grade 4 thrombocytopenia; grade 3 thrombocytopenia associated with bleeding requiring transfusion; grade 4 non-hematological treatment related event; grade 3 nausea/vomiting or diarrhea lasting \>/= 4 days despite corrective measures; grade 3 other non-hematological toxicities: anorexia, fatigue, hypertension only if G4 or not medically controlled and G3 peripheral sensory neuropathy that did not improve to G\<2 at time of retreatment; urinary protein excretion of \>3.5 gram per 24 hours that did not recover to \<2.0 gram per 24 hours within 2 weeks; symptomatic arterial thromboembolic events including cerebrovascular accidents, myocardial infarction, transient ischemic attacks, new onset or worsening of pre-existing angina.

    Time frame: Cycle 1 (Up to 3 weeks)

  2. Part 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy

    It describes the number of participants alive without progression at 6 months after the start of Aflibercept maintenance therapy.

    Time frame: 6 months after the start of maintenance therapy.

Secondary outcomes

  1. Part 1: Number of Participants With Tumor Responses (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD])

    Tumor assessment was performed by abdomino-pelvic computed tomography scan or magnetic resonance imaging (MRI) and chest X-ray or chest CT-scan to assess the disease status at baseline and then every 9 weeks during study treatment up to DP. Target lesions were evaluated using response evaluation criteria in solid tumors (RECIST) version 1.1, wherein CR = disappearance of all target lesions; PR = 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; PD =20% increase in the sum of the LD of target lesions taking as reference the smallest sum in the study and SD = small changes that did not meet above criteria.

    Time frame: Baseline and every 9 weeks up to DP (up to 15 months).

  2. Part 2: Progression Free Survival (PFS)

    PFS was defined as the time interval from the date of registration into the study to the date of first observation of DP or death (due to any cause), whichever was first.

    Time frame: From the date of enrollment up to the date of DP or death, whichever occurred first (up to 15 months).

  3. Part 2: Overall Survival (OS)

    OS was defined as the time interval from the date of registration into the study to the date of death due to any cause. In the absence of confirmation of death, survival time was to be censored at the earliest between the last date the participant was known to be alive and the end of study date.

    Time frame: From the date of enrollment up to the date of death (up to 15 months).

  4. Part 2: Overall Rate of Resectability of Metastatic Lesions

    Overall metastases resection rate was defined as the percentage of participants reaching an R0 metastases resection, defined as the complete absence of invasive carcinoma on histological examination at the time of definitive surgery.

    Time frame: 12 months after the last participant enrolled.

  5. Part 2: Number of Participants With CR or PR

    Tumor assessment was performed by abdomino-pelvic computed tomography scan or MRI and chest X-ray or chest CT-scan to assess the disease status at baseline and then every 9 weeks during study treatment up to DP. Target lesions were evaluated using RECIST version 1.1, wherein CR = disappearance of all target lesions; PR = 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: Baseline and every 9 weeks up to end of study completion (15 months).

  6. Part 2: Pharmacodynamic Parameters: Modulation of Circulating Analytes

    Blood and tumor samples were to be collected to evaluate the pharmacodynamic parameters including the assessment of the modulation of circulating analytes such as cytokines and angiogenic factors.

    Time frame: Baseline (within 21 days before registration); Day 1/pre-dose of Cycle 1, 2 and 3 of induction phase and maintenance phase; 30 ± 3 days after the last aflibercept administration.

  7. Part 2: Aflibercept Biomarkers Evaluation

    Blood and tumor samples were to be collected to evaluate proteomic biomarkers such as factors and receptors related to angiogenesis process, inflammation, and tumor progression.

    Time frame: Baseline (within 21 days before registration); Day 1/pre-dose of Cycle 1, 2 and 3 of induction phase and maintenance phase; 30 ± 3 days after the last aflibercept administration.

07

Results

Posted Apr 18, 2016
Limitations and caveats
The study enrollment was prematurely halted due to safety reasons.

Participant flow

The study was conducted at 2 sites in Italy. A total of 6 participants were screened between 17 Dec 2013 and 24 Feb 2014, out of which 4 participants were enrolled and treated.

Participant flow — Overall Study
MilestoneAflibercept + XELOX (Oxaliplatin and Capecitabine)
Started4
Completed4
Not completed0

Outcome measures

PrimaryPart 1: Number of Participants With Dose Limiting Toxicities (DLTs)

DLTs were assessed using the national cancer institute (NCI) common terminology criteria for adverse events (CTCAE) version 4.03. DLTs were defined as any of following AEs: grade 4 neutropenia lasting \>7 consecutive days; febrile neutropenia or neutropenic infection; grade 4 thrombocytopenia; grade 3 thrombocytopenia associated with bleeding requiring transfusion; grade 4 non-hematological treatment related event; grade 3 nausea/vomiting or diarrhea lasting \>/= 4 days despite corrective measures; grade 3 other non-hematological toxicities: anorexia, fatigue, hypertension only if G4 or not medically controlled and G3 peripheral sensory neuropathy that did not improve to G\<2 at time of retreatment; urinary protein excretion of \>3.5 gram per 24 hours that did not recover to \<2.0 gram per 24 hours within 2 weeks; symptomatic arterial thromboembolic events including cerebrovascular accidents, myocardial infarction, transient ischemic attacks, new onset or worsening of pre-existing angina.

Time frame:
Cycle 1 (Up to 3 weeks)
Reported as:
Number · Participants
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsAflibercept + XELOX (Oxaliplatin and Capecitabine)
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)1
PrimaryPart 2: Number of Participants With Progression Free Survival (PFS) at 6 Months After the Start of Maintenance Therapy

It describes the number of participants alive without progression at 6 months after the start of Aflibercept maintenance therapy.

Time frame:
6 months after the start of maintenance therapy.

No measurements were reported for this outcome.

SecondaryPart 1: Number of Participants With Tumor Responses (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD])

Tumor assessment was performed by abdomino-pelvic computed tomography scan or magnetic resonance imaging (MRI) and chest X-ray or chest CT-scan to assess the disease status at baseline and then every 9 weeks during study treatment up to DP. Target lesions were evaluated using response evaluation criteria in solid tumors (RECIST) version 1.1, wherein CR = disappearance of all target lesions; PR = 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD; PD =20% increase in the sum of the LD of target lesions taking as reference the smallest sum in the study and SD = small changes that did not meet above criteria.

Time frame:
Baseline and every 9 weeks up to DP (up to 15 months).
Reported as:
Number · Participants
Part 1: Number of Participants With Tumor Responses (Complete Response [CR], Partial Response [PR], Stable Disease [SD] or Progressive Disease [PD])
ParticipantsAflibercept + XELOX (Oxaliplatin and Capecitabine)
CR0
PR1
PD0
SD3
SecondaryPart 2: Progression Free Survival (PFS)

PFS was defined as the time interval from the date of registration into the study to the date of first observation of DP or death (due to any cause), whichever was first.

Time frame:
From the date of enrollment up to the date of DP or death, whichever occurred first (up to 15 months).

No measurements were reported for this outcome.

SecondaryPart 2: Overall Survival (OS)

OS was defined as the time interval from the date of registration into the study to the date of death due to any cause. In the absence of confirmation of death, survival time was to be censored at the earliest between the last date the participant was known to be alive and the end of study date.

Time frame:
From the date of enrollment up to the date of death (up to 15 months).

No measurements were reported for this outcome.

SecondaryPart 2: Overall Rate of Resectability of Metastatic Lesions

Overall metastases resection rate was defined as the percentage of participants reaching an R0 metastases resection, defined as the complete absence of invasive carcinoma on histological examination at the time of definitive surgery.

Time frame:
12 months after the last participant enrolled.

No measurements were reported for this outcome.

SecondaryPart 2: Number of Participants With CR or PR

Tumor assessment was performed by abdomino-pelvic computed tomography scan or MRI and chest X-ray or chest CT-scan to assess the disease status at baseline and then every 9 weeks during study treatment up to DP. Target lesions were evaluated using RECIST version 1.1, wherein CR = disappearance of all target lesions; PR = 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
Baseline and every 9 weeks up to end of study completion (15 months).

No measurements were reported for this outcome.

SecondaryPart 2: Pharmacodynamic Parameters: Modulation of Circulating Analytes

Blood and tumor samples were to be collected to evaluate the pharmacodynamic parameters including the assessment of the modulation of circulating analytes such as cytokines and angiogenic factors.

Time frame:
Baseline (within 21 days before registration); Day 1/pre-dose of Cycle 1, 2 and 3 of induction phase and maintenance phase; 30 ± 3 days after the last aflibercept administration.

No measurements were reported for this outcome.

SecondaryPart 2: Aflibercept Biomarkers Evaluation

Blood and tumor samples were to be collected to evaluate proteomic biomarkers such as factors and receptors related to angiogenesis process, inflammation, and tumor progression.

Time frame:
Baseline (within 21 days before registration); Day 1/pre-dose of Cycle 1, 2 and 3 of induction phase and maintenance phase; 30 ± 3 days after the last aflibercept administration.

No measurements were reported for this outcome.

Adverse events

Collected over All AEs were collected from signature of the informed consent form up to 30 days after the last administration of treatment regardless of seriousness or relationship to study treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept + XELOX (Oxaliplatin and Capecitabine)—3/4 (75%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventAflibercept + XELOX (Oxaliplatin and Capecitabine)
HypertensionVascular disorders3/4
Acute coronary syndromeCardiac disorders1/4
FatigueGeneral disorders1/4
Most frequent other events
Showing 10 of 35
Most frequent other events
EventAflibercept + XELOX (Oxaliplatin and Capecitabine)
ConstipationGastrointestinal disorders2/4
DiarrhoeaGastrointestinal disorders2/4
NauseaGastrointestinal disorders2/4
AstheniaGeneral disorders2/4
Decreased appetiteMetabolism and nutrition disorders2/4
HeadacheNervous system disorders2/4
HiccupsRespiratory, thoracic and mediastinal disorders2/4
BradycardiaCardiac disorders1/4
Abdominal painGastrointestinal disorders1/4
HaemorrhoidsGastrointestinal disorders1/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Aflibercept + XELOX (Oxaliplatin and Capecitabine)
<=18 years0
Between 18 and 65 years0
>=65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept + XELOX (Oxaliplatin and Capecitabine)
Female0
Male4
08

Study locations

2 sites
  • Investigational Site Number 380-001
    Genova, 16132, Italy
  • Investigational Site Number 380-002
    Milano, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2013
First posted
Oct 7, 2013
Start
Dec 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Apr 18, 2016
Last update
Apr 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01955629
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 7, 2013
Start date
Dec 2013
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Apr 18, 2016
Last update
Apr 18, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aflibercept · Oxaliplatin · Capecitabine

Start the discussion